IQVIA HOLDINGS INC. (IQV) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value 1.44%; Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value 2.91×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.44% | Share-based compensation / revenue. Period ending 2026-03-31. $240.00M ÷ $16.63B × 100 ≈ 1.44% |
| Interest coverage · 12 months | 2.91× | Operating income ÷ reported interest expense. $2.20B ÷ $756.00M ≈ 2.91× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 16.63B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 240.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 2.20B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 756.00M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $16.63B | $240.00M | $2.20B | $756.00M | (m) | 1.44% | 2.91× | Reported |
| 2025-12-31 | (m) | $16.31B | $247.00M | $2.18B | $729.00M | (m) | 1.51% | 2.99× | Reported |
| 2025-09-30 | (m) | $15.90B | $235.00M | $2.18B | $707.00M | (m) | 1.48% | 3.08× | Reported |
| 2025-06-30 | (m) | $15.70B | $234.00M | $2.18B | $688.00M | (m) | 1.49% | 3.17× | Reported |
| 2025-03-31 | (m) | $15.50B | $222.00M | $2.19B | $669.00M | (m) | 1.43% | 3.28× | Reported |
| 2024-12-31 | (m) | $15.40B | $206.00M | $2.20B | $670.00M | (m) | 1.34% | 3.29× | Reported |
| 2024-09-30 | (m) | $15.31B | $203.00M | $2.08B | $680.00M | (m) | 1.33% | 3.05× | Reported |
| 2024-06-30 | (m) | $15.15B | $196.00M | $2.01B | $691.00M | (m) | 1.29% | 2.91× | Reported |
| 2024-03-31 | (m) | $15.07B | $198.00M | $2.01B | $697.00M | (m) | 1.31% | 2.89× | Reported |
| 2023-12-31 | (m) | $14.98B | $217.00M | $1.98B | $672.00M | (m) | 1.45% | 2.94× | Reported |
| 2023-09-30 | (m) | $14.86B | $230.00M | $1.85B | $619.00M | (m) | 1.55% | 3.00× | Reported |
| 2023-06-30 | (m) | $14.68B | $244.00M | $1.85B | $546.00M | (m) | 1.66% | 3.38× | Reported |
| 2023-03-31 | (m) | $14.49B | $239.00M | $1.77B | $471.00M | (m) | 1.65% | 3.77× | Reported |
| 2022-12-31 | (m) | $14.41B | $194.00M | $1.80B | $416.00M | (m) | 1.35% | 4.32× | Reported |
| 2022-09-30 | (m) | $14.31B | $178.00M | $1.88B | $378.00M | (m) | 1.24% | 4.98× | Reported |
| 2022-06-30 | (m) | $14.14B | $165.00M | $1.71B | $362.00M | (m) | 1.17% | 4.73× | Reported |
| 2022-03-31 | (m) | $14.03B | $168.00M | $1.55B | $362.00M | (m) | 1.20% | 4.27× | Reported |
| 2021-12-31 | (m) | $13.87B | $170.00M | $1.39B | $375.00M | (m) | 1.23% | 3.71× | Reported |
| 2021-09-30 | (m) | $13.54B | $154.00M | $1.22B | $387.00M | (m) | 1.14% | 3.15× | Reported |
| 2021-06-30 | (m) | $12.93B | $139.00M | $1.10B | $395.00M | (m) | 1.07% | 2.79× | Reported |
| 2021-03-31 | (m) | $12.01B | $127.00M | $880.00M | $409.00M | (m) | 1.06% | 2.15× | Reported |
| 2020-12-31 | (m) | $11.36B | $95.00M | $731.00M | $416.00M | (m) | 0.84% | 1.76× | Reported |
| 2020-09-30 | (m) | $10.96B | $128.00M | $608.00M | $423.00M | (m) | 1.17% | 1.44× | Reported |
| 2020-06-30 | (m) | $10.94B | $122.00M | $625.00M | $437.00M | (m) | 1.12% | 1.43× | Reported |
| 2020-03-31 | (m) | $11.16B | $120.00M | $760.00M | $443.00M | (m) | 1.08% | 1.72× | Reported |
| 2019-12-31 | (m) | $11.09B | $146.00M | $777.00M | $447.00M | (m) | 1.32% | 1.74× | Reported |
| 2019-09-30 | (m) | $10.88B | $122.00M | $818.00M | $444.00M | (m) | 1.12% | 1.84× | Reported |
| 2019-06-30 | (m) | $10.71B | $126.00M | $795.00M | $435.00M | (m) | 1.18% | 1.83× | Reported |
| 2019-03-31 | (m) | $10.53B | $118.00M | $768.00M | $428.00M | (m) | 1.12% | 1.79× | Reported |
| 2018-12-31 | (m) | $10.41B | $113.00M | $741.00M | $414.00M | (m) | 1.09% | 1.79× | Reported |
| 2018-09-30 | (m) | $10.28B | $102.00M | $730.00M | $405.00M | (m) | 0.99% | 1.80× | Reported |
| 2018-06-30 | (m) | $10.15B | $100.00M | $744.00M | $393.00M | (m) | 0.98% | 1.89× | Reported |
| 2018-03-31 | (m) | $9.94B | $101.00M | $700.00M | $367.00M | (m) | 1.02% | 1.91× | Reported |
| 2017-12-31 | (m) | $9.74B | $106.00M | $719.00M | $346.00M | (m) | 1.09% | 2.08× | Reported |
| 2017-09-30 | (m) | $9.50B | $128.00M | $661.00M | $320.00M | (m) | 1.35% | 2.07× | Reported |
| 2017-06-30 | (m) | $8.53B | $114.00M | $632.00M | $252.00M | (m) | 1.34% | 2.51× | Reported |
| 2017-03-31 | (m) | $7.71B | $97.00M | $631.00M | $193.00M | (m) | 1.26% | 3.27× | Reported |
| 2016-12-31 | (m) | $6.88B | $80.00M | $642.00M | $144.00M | (m) | 1.16% | 4.46× | Reported |
| 2016-09-30 | (m) | $6.06B | $43.41M | $675.29M | $98.48M | (m) | 0.72% | 6.86× | Reported |
| 2016-06-30 | (m) | $5.99B | $36.20M | $674.54M | $99.41M | (m) | 0.60% | 6.79× | Reported |
| 2016-03-31 | (m) | $5.88B | $36.87M | $682.19M | $102.41M | (m) | 0.63% | 6.66× | Reported |
| 2015-12-31 | $3.34M | $5.74B | $37.76M | $646.61M | $101.79M | 0.06% | 0.66% | 6.35× | Reported |
| 2015-09-30 | (m) | $5.63B | $36.31M | $627.56M | $-98.89M | (m) | 0.65% | (m) | Reported |
| 2015-06-30 | (m) | $5.60B | $34.72M | $609.68M | $-99.26M | (m) | 0.62% | (m) | Reported |
| 2015-03-31 | (m) | $5.50B | $32.35M | $592.29M | $-99.95M | (m) | 0.59% | (m) | Reported |
| 2014-12-31 | $5.79M | $5.46B | $30.00M | $590.39M | $-100.59M | 0.11% | 0.55% | (m) | Reported |
| 2014-09-30 | (m) | $5.43B | $28.25M | $558.47M | $101.38M | (m) | 0.52% | 5.51× | Reported |
| 2014-06-30 | (m) | $5.22B | $27.34M | $534.59M | $105.08M | (m) | 0.52% | 5.09× | Reported |
| 2014-03-31 | (m) | $5.18B | $25.57M | $488.48M | $112.17M | (m) | 0.49% | 4.35× | Reported |
| 2013-12-31 | $4.96M | $5.10B | $22.83M | $462.33M | $123.51M | 0.10% | 0.45% | 3.74× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $10.43M | $4.87B | $25.93M | $396.44M | $134.37M | 0.21% | 0.53% | 2.95× | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $9.99M | $4.33B | $14.13M | $345.25M | $109.06M | 0.23% | 0.33% | 3.17× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |